Featured Articles
Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]
CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]
Recognized for innovation in powering small molecule drug discovery with AI, Atomwise among the Top-10 in Biotechnology category SAN FRANCISCO, Calif. — March 9, 2021 — Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company’s prestigious annual list of the World’s Most […]
Atomwise unveils a growing portfolio of emerging joint venture companies, with programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Atomwise CEO and joint venture companies are scheduled to speak at Informa’s Biotech Showcase from January 11-15, 2021 during J.P. Morgan Healthcare Week. SAN FRANCISCO, Calif., December 21, 2020 – Atomwise, the leader in […]